Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study

• Asıl Yazarlar: Maud Lemoine, PhD (Yazar), Yusuke Shimakawa, PhD (Yazar), Ramou Njie, PhD (Yazar), Makie Taal, MSc (Yazar), Gibril Ndow, MD (Yazar), Isabelle Chemin, PhD (Yazar), Sumantra Ghosh, PhD (Yazar), Harr F Njai, PhD (Yazar), Adam Jeng, BSc (Yazar), Amina Sow, PhD (Yazar), Prof. Coumba Toure-Kane, PhD (Yazar), Prof. Souleymane Mboup, PhD (Yazar), Penda Suso, BSc (Yazar), Saydiba Tamba (Yazar), Abdullah Jatta (Yazar), Louise Sarr, MD (Yazar), Aboubacar Kambi, MD (Yazar), William Stanger, Bsc (Yazar), Shevanthi Nayagam, MD (Yazar), Jessica Howell, PhD (Yazar), Liliane Mpabanzi, PhD (Yazar), Prof. Ousman Nyan, MD (Yazar), Prof. Tumani Corrah, PhD (Yazar), Prof. Hilton Whittle, PhD (Yazar), Prof. Simon D Taylor-Robinson, PhD (Yazar), Prof. Umberto D'Alessandro, PhD (Yazar), Maimuna Mendy, PhD (Yazar), Prof. Mark R Thursz, MD (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Elsevier, 2016-08-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Despite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, HBV-related morbidity and mortality remain high in sub-Saharan Africa. Identification and treatment of asymptomatic people with chronic HBV infection should reduce the disease burden. We therefore assessed...